- Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022.
- Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma.
- The global multiple myeloma market is expected to reach $19.8 billion by 2027.
- Most recent partnership for SpringWorks' Nirogacestat was with AbbVie, and it becomes 7th one targeting patients with multiple myeloma.
For further details see:
SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline